secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001558370-25-010523
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q2 revenue down 18% YoY; lowers 2025 core revenue guidance
------------------------------------------------------------------

- Total revenue $8.5M, down 18% YoY; core revenue up 8% to $8.2M.
- Net loss $12.4M vs $9.4M loss in Q2 2024; operating expenses $21.2M.
- Added two SPL clients in July (Adicet Bio, Anocca AB); total SPL agreements now 31.
- Updated FY2025: core revenue flat to -10% YoY; SPL Program-related revenue ~$5M.
- Expects year-end cash ≥ $155M; cites customer inventory, reprioritization headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025010523/0001558370-25-010523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025010523/mxct-20250806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer